Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Prostate carcinoma (PCa) is a significant health concern.
• CpG methylation is a key epigenetic mechanism involved in cancer development.
• Tumor suppressive genes can be silenced by aberrant methylation patterns.

Purpose of the Study:

• To identify tumor suppressive genes silenced by CpG methylation in prostate cancer.
• To investigate the role of 14-3-3sigma gene epigenetic silencing in PCa progression.

Main Methods:

• Genome-wide expression analysis using microarray after pharmacological reversal of CpG methylation.
• Laser microdissection to isolate prostatic tissue cell types.
• Methylation-specific PCR analysis to detect 14-3-3sigma CpG methylation.
• RNA interference to assess the functional impact of 14-3-3sigma inactivation.

Main Results:

• Epigenetic silencing of the 14-3-3sigma gene was detected in PCa cell lines.
• CpG methylation of 14-3-3sigma was found in all analyzed primary PCa samples, correlating with decreased protein expression.
• Normal prostate and benign hyperplasia cells exhibited high 14-3-3sigma expression, while PCa precursor lesions showed reduced levels.
• Inactivation of 14-3-3sigma impaired DNA damage-induced cell cycle arrest.

Conclusions:

• CpG methylation and subsequent downregulation of 14-3-3sigma expression are common in prostate cancer.
• This epigenetic silencing likely contributes to PCa development by facilitating escape from DNA damage-induced cell cycle arrest, potentially linked to telomere shortening.